PROCEPT BioRobotics(R) to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

PROCEPT BioRobotics(R) to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City GlobeNewswire January 26, 2026 SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative […]

Brompton Funds Special Year End Distribution Update

Brompton Funds Special Year End Distribution Update GlobeNewswire January 26, 2026 TORONTO, Jan. 26, 2026 (GLOBE NEWSWIRE) — (TSX: BBBB, KNGC, KNGU, KNGX) – On December 17, 2025, Brompton Funds announced special year end estimated distributions for Brompton Wellington Square Investment Grade CLO ETF, Brompton Canadian Cash Flow Kings ETF, Brompton U.S. Cash Flow Kings

Working Advantage Survey: Nearly 80% of Employers Plan to Maintain or Increase Benefits in 2026

Aventura, FL, Jan. 26, 2026 (GLOBE NEWSWIRE) — Employers spent 2025 navigating a variety of challenges, not the least of which were heavy economic pressure and high cost sensitivity. As a result, some large enterprises (especially in the tech sector) enacted massive layouts. Yet 2026 isn't looking to be a year of widespread corporate cost-cutting.

Working Advantage Survey: Nearly 80% of Employers Plan to Maintain or Increase Benefits in 2026

Working Advantage Survey: Nearly 80% of Employers Plan to Maintain or Increase Benefits in 2026 GlobeNewswire January 26, 2026 Aventura, FL, Jan. 26, 2026 (GLOBE NEWSWIRE) — Employers spent 2025 navigating a variety of challenges, not the least of which were heavy economic pressure and high cost sensitivity. As a result, some large enterprises (especially

The FUTR Corporation Appoints Alex McDougall as Chief Executive Officer

Toronto, Ontario–(Newsfile Corp. – January 26, 2026) – The FUTR Corporation (TSXV: FTRC) (OTCQB: FTRCF) (FSE: QA20) (WKN: A4165Y) (ISIN: CA3609521057) (“FUTR” or the “Company”), creator of the FUTR Agent App which enables users to store, manage, access, and monetize their personal information and make real-time payments, today announced the appointment of Alex McDougall as

Sanmina Reports First Quarter Fiscal 2026 Financial Results

Sanmina Corporation (“Sanmina” or the “Company”) (NASDAQ: SANM), a leading integrated manufacturing solutions company, today reported financial results for the first quarter ended December 27, 2025 and outlook for its second fiscal quarter ending March 28, 2026. First Quarter Fiscal 2026 Financial Highlights — Revenue: $3.19 billion — GAAP operating margin: 2.3% — GAAP diluted

QVC Group, Inc. Announces Fourth Quarter Earnings Release and Conference Call

QVC Group, Inc. (“QVC Group”) (Nasdaq: QVCGA, QVCGP; OTCQB: QVCGB) will host a conference call to discuss results for the fourth quarter of 2025 on Thursday, February 26th at 8:30 a.m. E.T. Before the open of market trading that day, QVC Group will issue a press release reporting such results, which can be found at

AGNC Investment Corp. Announces Fourth Quarter 2025 Financial Results

AGNC Investment Corp. (“AGNC” or the “Company”) (Nasdaq: AGNC) today announced financial results for the quarter ended December 31, 2025. FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS — $0.89 comprehensive income per common share, comprised of: — $0.83 net income per common share — $0.06 other comprehensive income (“OCI”) per common share on investments marked-to-market through OCI

Royce Global Trust (NYSE: RGT) as of Dec 31, 2025

— A closed-end fund that invests in global equities using a disciplined value approach — Average weekly trading volume of approximately 110,157 shares — Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 12/31/25 NAV 15.24 MKT 13.11 AVERAGE ANNUAL TOTAL RETURN AS OF 12/31/25 NAV (%)

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:CCCC), WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase

Scroll to Top